Oric Pharmaceuticals Inc - Asset Resilience Ratio
Oric Pharmaceuticals Inc (ORIC) has an Asset Resilience Ratio of 51.64% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Oric Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Check ORIC capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Oric Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Oric Pharmaceuticals Inc stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $225.54 Million | 51.64% |
| Total Liquid Assets | $225.54 Million | 51.64% |
Asset Resilience Insights
- Very High Liquidity: Oric Pharmaceuticals Inc maintains exceptional liquid asset reserves at 51.64% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Oric Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Oric Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Oric Pharmaceuticals Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Oric Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 57.38% | $235.82 Million | $411.00 Million | -14.32pp |
| 2024-12-31 | 71.70% | $196.55 Million | $274.14 Million | -0.86pp |
| 2023-12-31 | 72.56% | $184.80 Million | $254.69 Million | +16.87pp |
| 2022-12-31 | 55.69% | $139.43 Million | $250.36 Million | +52.02pp |
| 2021-12-31 | 3.67% | $10.97 Million | $298.64 Million | -68.28pp |
| 2020-12-31 | 71.96% | $215.15 Million | $299.00 Million | -- |
About Oric Pharmaceuticals Inc
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target… Read more